✦ LIBER ✦

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial

✍ Scribed by Thomas J. Povsic; Mauricio G. Cohen; Roxana Mehran; Christopher E. Buller; Christoph Bode; Jan H. Cornel; Jarosław D. Kasprzak; Gilles Montalescot; Diane Joseph; William A. Wargin; Christopher P. Rusconi; Steven L. Zelenkofske; Richard C. Becker; John H. Alexander

Book ID: 116192337
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 448 KB
Volume: 161
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2010.10.022

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The efficacy and safety of rituximab in

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

✍ Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek S 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB 👁 2 views

Rationale and design of the Anti-Xa Ther

Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

✍ C. Michael Gibson; Jessica L. Mega; Paul Burton; Shinya Goto; Freek Verheugt; Ch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 428 KB